Dynavax Technologies Corporation

Dynavax Technologies — Proxy Contest (May 2025)

51 slides from Dynavax Technologies's proxy contest presentation, May 12, 2025

  1. Slide 1: Dynavax's Strategy Offers a Superior Path for Delivering Stockholder Value

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax’s Strategy Offers a Superior Path for D elivering Stockholder Value Investor Presentation: May 2025

  2. Slide 2: Disclaimer

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Disclaimer © Copyright DYNAVAX 2025 2 | About Dynavax Dynavax is a commercial - stage biopharmaceutical company de

  3. Slide 3: Dynavax is Delivering Superior Value for Stockholders

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax is Delivering Superior Value for Stockholders 3 | Following Our Successful Pivot, Dynavax is Delivering fo

  4. Slide 4: Following Our Successful Pivot, Dynavax is Delivering for Stockholders

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 4 | Following Our Successful Pivot, Dynavax is Delivering for Stockholders

  5. Slide 5: Re-focused Strategy from Immuno-Oncology to Commercial Vaccine Business

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx z 5 | © Copyright DYNAVAX 2025 Re - focused Strategy from Immuno - Oncology to Commercial Vaccine Business Leaned

  6. Slide 6: HEPLISAV-B Has Quickly Overtaken Incumbent Market Leader GSK's ENGERIX-B

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx HEPLISAV - B Has Quickly Overtaken Incumbent Market Leader GSK’s ENGERIX - B Vaccine 2 Doses in 1 Month x v s. 3 d

  7. Slide 7: We Didn't Merely Survive Through the Pandemic – We Thrived

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 We Didn’t Merely Survive Through the Pandemic – We Thrived Our Operations Have Delivered

  8. Slide 8: We Are Progressing a Promising Clinical Vaccine Pipeline Powered by our Differentiated CpG Adjuvant

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx z Opportunity: CpG 1018 adjuvant may improve Shingles vaccine tolerability while maintaining efficacy due to abili

  9. Slide 9: We Have a Strong Foundation for Growth Which Should Not Be Undervalued

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx We Have a Strong Foundation for Growth Which Should Not Be Undervalued Invest in Our Innovative Pipeline and Comme

  10. Slide 10: Our Strategy and Execution Are Increasingly Driving Substantial Stockholder Value

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx (7.2)% (100)% (50)% 0 % 50 % 100 % 150 % 200 % 250 % May-2019 May-2020 May-2021 May-2022 May-2023 May-2024 62.4 %

  11. Slide 11: Analysts Have High Confidence In Management's Ability to Execute and Focus on HEPLISAV-B

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Analysts Have High Confidence In Management’s Ability to Execute and Focus on HEPLISAV - B… © Copyright DYNAVAX 20

  12. Slide 12: And Are Excited About Dynavax's Promising Internal Clinical Pipeline

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx … And Are Excited About Dynavax’s Promising Internal Clinical Pipeline and Value Creation Opportunities © Copyrigh

  13. Slide 13: Both Internal and External Innovation Will Be Integral to Long Term Success

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Both Internal and External Innovation Will B e Integral to Long Term Success © Copyright DYNAVAX 2025 S ource: Dyn

  14. Slide 14: Our Strategy

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Identify Strategic Opportunities to Accelerate Growth • Continue disciplined allocation of capital aligned with co

  15. Slide 15: Our Differentiated Expertise and Capabilities Will Enable Us to Succeed

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 15 | © Copyright DYNAVAX 2025 Our Differentiated Expertise and Capabilities Will Enable Us to Succeed Superior Tec

  16. Slide 16: Foundational Principles of Corporate Finance Underpin our Capital Allocation Framework

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 16 | Foundational Principles of Corporate Finance Underpin our Capital Allocation Framework © Copyright DYNAVAX 20

  17. Slide 17: We Are One of the Few Vaccine Companies to Return Meaningful Capital to Stockholders

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 53% 97% 60% 98% 82% 100% 3% 36% 2% 47% 4% 18% Dynavax Technologies Novavax Bavarian Nordic Valneva Emergent BioSol

  18. Slide 18: Investing in Growth and Opportunistic Capital Return are Not Mutually Exclusive

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 18 | Investing in Growth and Opportunistic Capital Return are n ot Mutually Exclusive Investing in Attractive Oppo

  19. Slide 19: This is the Optimal Board to Drive our Value Creation Potential

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx This is the Optimal Board to Drive our Value Creation Potential 19 |

  20. Slide 20: Board Track Record of Commercialization, Pipeline, Business Development and Capital Returns

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx P Highly Successful Commercialization of a Market - Leading Vaccine: HEPLISAV - B is now the market share leader i

  21. Slide 21: Proactive Board Refreshment Has Been Key to Our Success

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 2019 2020 2021 2022 2023 2024 2025 Ryan Spencer Brent MacGregor Peter Paradiso Scott Myers Elaine Sun Emilio Emini

  22. Slide 22: Director Backgrounds and Expertise

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Daniel Kisner Compensation Committee Lauren Silvernail • 30+ years of experience leading finance, commercializatio

  23. Slide 23: With the Right Skills and Experiences to Continue Driving Long-Term Value

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Scott Myers (Chairman) Ryan Spencer (CEO) Francis Cano Emilio Emini Daniel Kisner Brent MacGregor Peter Paradiso L

  24. Slide 24: Replacing Any of Our Directors With Deep Track Nominees Would Remove Vital Expertise

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Lauren Silvernail Independent Director Elaine Sun Independent Director Brent MacGregor Independent Director Scott

  25. Slide 25: Deep Track's Plan Threatens Growth and Puts Future Stockholder Value at Risk

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track’s Plan Threatens Growth and Puts Future Stockholder Value at Risk 25 |

  26. Slide 26: Deep Track's One-Dimensional Plan Threatens Stockholder Value

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track’s One - Dimensional “Plan” Threatens Stockholder Value © Copyright DYNAVAX 2025 Our Strategy Deep Track

  27. Slide 27: If Deep Track Truly Wanted to Fix the Company, It is Five Years Too Late

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx O Monetize HEPLISAV - B exclusively for capital return by over - levering the Company with high - cost debt Increa

  28. Slide 28: Deep Track Distorts the Facts to Fit its Narrative About Our Performance

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 203 % 0 % 100 % 200 % 300 % 400 % 500 % 600 % Apr-2020 Apr-2021 Apr-2022 Apr-2023 Apr-2024 Apr-2025 Indexed TSR 20

  29. Slide 29: Deep Track's Distortions Don't Stop There (1/3)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 Deep Track’s Distortions Don’t Stop There (1/3) 29 | Deep Track claims our strategic pivo

  30. Slide 30: Deep Track's Distortions Don't Stop There (2/3)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 0% 100% 200% 300% 400% 1-Jan-21 1-Jan-22 1-Jan-23 1-Jan-24 31-Dec-24 187% 1 © Copyright DYNAVAX 2025 Deep Track’s

  31. Slide 31: Deep Track's Distortions Don't Stop There (3/3)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 Deep Track’s Distortions Don’t Stop There (3/3) 31 | 15% of 8% is 1.2% of total CEO compe

  32. Slide 32: Correcting Deep Track's False and Misleading Claims (1/2)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 Correcting Deep Track’s False and Misleading Claims (1/2) Dynavax’s management team is di

  33. Slide 33: Correcting Deep Track's False and Misleading Claims (2/2)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 Correcting Deep Track’s False and Misleading Claims (2/2) Dynavax should have used cash t

  34. Slide 34: Settlement Proposals Timeline

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 34 | Dynavax Proposal #1 (1/22) Deep Track Counter Proposal (1/22) Dynavax Proposal #2 (1/25) Deep Track Response

  35. Slide 35: Deep Track insisted on direct Board representation and unrestricted path to control

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track insisted it have direct Board representation now, and be unrestricted in its path to control the Board

  36. Slide 36: But Deep Track Would Not Negotiate in Good Faith (1/3)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track immediately rejected our proposal and insisted in greater representation and new conditions Deep Track

  37. Slide 37: But Deep Track Would Not Negotiate in Good Faith (2/3)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track presented a counteroffer with terms far worse than any of their prior counteroffers and introduced new

  38. Slide 38: But Deep Track Would Not Negotiate in Good Faith (3/3)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track continued to insist on the appointment of Brett Erkman and failed to offer an appropriate standstill …B

  39. Slide 39: Deep Track's Campaign Would Remove Proven Strategic Leadership

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track’s Campaign Would Remove Proven Strategic Leadership at a Critical Moment 39 | Scott Myers Independent C

  40. Slide 40: Deep Track's Campaign Would Remove Essential Vaccine Expertise

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Unique perspective in drug development and commercialization and 20+ years of experience are essential to Dynavax

  41. Slide 41: Deep Track's Campaign Would Remove Senior Public Biotech and Deal Experience

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Michael Mullette Former Interim CEO of Lykos Therapeutics, a privately - held pharmaceutical company developing MD

  42. Slide 42: Deep Track's Campaign Would Remove Deep Industry Financial Expertise

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 30+ years in finance including strategic planning, and capital raising for biotechnology companies, as well as exp

  43. Slide 43: We Are Executing a Clear Strategy That is Generating Record Results

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx We Are Executing a Clear Strategy That is Generating Record Results and Delivering Strong Returns For Stockholders

  44. Slide 44: Dynavax is Delivering Superior Value for Stockholders

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax is Delivering Superior Value for Stockholders © Copyright DYNAVAX 2025

  45. Slide 45: Dynavax is Delivering Superior Value for Stockholders

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax is Delivering Superior Value for Stockholders 45 | Following Our Successful Pivot, Dynavax is Delivering f

  46. Slide 46: Reject Deep Track's Attempt to Take Control of Dynavax

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 46 | Reject Deep Track’s Attempt to Take Control of Dynavax Vote on the GOLD proxy card for Dynavax’s Board Nomine

  47. Slide 47: Appendix

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Appendix 47 |

  48. Slide 48: Dynavax's Innovative Vaccines Protect Patients Across The Globe

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax’s Innovative Vaccines Protect Patients Across The Globe From Infectious Diseases © Copyright DYNAVAX 2025

  49. Slide 49: HEPLISAV-B Market Opportunity Expected to Grow to Over $900M in U.S. by 2030

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Source: Internal data and company estimates. Not independently verified. 1 Based on 202 4 U.S. adult hepatitis B v

  50. Slide 50: Deep Track's Distortions Don't Stop There (Cont'd)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track Investor Presentation – page 13 filed May 5, 2025 © Copyright DYNAVAX 2025 Deep Track’s Distortions Don

  51. Slide 51: Deep Track's Distortions Don't Stop There (Cont'd)

    ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx ” We will not agree to any settlement which removes what we have now , and what the company is legally obligated t

Dynavax Technologies — Proxy Contest (May 2025) on 6ix